Pfizer (PFE) EBT Margin (2009 - 2026)

Pfizer (PFE) has reported EBT Margin for 18 consecutive years, with 4.34% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT Margin fell 2512.0% year-over-year to 4.34% in Q2 2026; TTM through Jun 2026 was 6.61%, a 911.0% decrease from a year earlier, with the FY2025 full-year figure at 12.02%, down 59.0% from the prior year.
• EBT Margin was 4.34% for Q2 2026 at Pfizer, down from 21.94% in the prior quarter.
• Over five years, EBT Margin peaked at 41.26% in Q3 2022 and troughed at 120.24% in Q4 2023.
• A 5-year average of 8.34% and a median of 20.16% in 2025 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin soared 2155 bps in 2025 and sank 2512 bps in 2026, its largest moves.
• Over 5 years, EBT Margin stood at 41.26% in 2022, then sank by 391 bps to 120.24% in 2023, then soared by 115 bps to 17.51% in 2024, then plunged by 153 bps to 9.35% in 2025, then surged by 54 bps to 4.34% in 2026.
• The last three EBT Margin figures came in at 4.34% (Q2 2026), 21.94% (Q1 2026), and 9.35% (Q4 2025), per Business Quant data.